Bristol-Myers Squibb Co
NYSE:BMY
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
39.46
59.82
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Bristol-Myers Squibb Co
Bristol-Myers Squibb Co
Revenue
Bristol-Myers Squibb Co
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Revenue
$47.4B
|
CAGR 3-Years
1%
|
CAGR 5-Years
14%
|
CAGR 10-Years
11%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Revenue
$87.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Pfizer Inc
NYSE:PFE
|
Revenue
$60.1B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
14%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Revenue
$63.2B
|
CAGR 3-Years
11%
|
CAGR 5-Years
7%
|
CAGR 10-Years
4%
|
|
|
Zoetis Inc
NYSE:ZTS
|
Revenue
$9.2B
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
7%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Revenue
$40.9B
|
CAGR 3-Years
14%
|
CAGR 5-Years
13%
|
CAGR 10-Years
7%
|
|
Bristol-Myers Squibb Co
Revenue Breakdown
Breakdown by Geography
Bristol-Myers Squibb Co
|
Total Revenue:
45B
USD
|
|
United States:
31.6B
USD
|
|
International:
12.8B
USD
|
|
Other:
699m
USD
|
Breakdown by Segments
Bristol-Myers Squibb Co
Bristol-Myers Squibb Co
Glance View
Bristol-Myers Squibb Co. (BMS) is a global biopharmaceutical company renowned for its innovative approach to discovering and developing transformative medicines. Founded over 160 years ago, BMS has built a robust portfolio that includes therapies across oncology, immunology, cardiovascular disease, and infectious diseases, focusing on addressing unmet medical needs. The company is celebrated for its substantial investments in research and development, which have led to groundbreaking treatments like Opdivo and Eliquis. These products have not only propelled revenue growth but also established BMS as a key player in the life sciences sector, showcasing its commitment to advancing the health and well-being of patients around the world. For investors, BMS presents a compelling opportunity rooted in a strong pipeline and strategic partnerships. The company has navigated recent challenges, including patent expirations, by fostering innovation and expanding its therapeutic offerings through mergers and acquisitions. In the ever-evolving healthcare landscape, BMS aims to leverage its scientific expertise and market presence to drive sustainable growth. With a focus on maintaining a balanced portfolio and a disciplined approach to capital allocation, Bristol-Myers Squibb stands out as a resilient entity poised to deliver long-term value, supported by a robust pipeline expected to bring additional blockbuster products to market in the coming years.
See Also
What is Bristol-Myers Squibb Co's Revenue?
Revenue
47.4B
USD
Based on the financial report for Sep 30, 2024, Bristol-Myers Squibb Co's Revenue amounts to 47.4B USD.
What is Bristol-Myers Squibb Co's Revenue growth rate?
Revenue CAGR 10Y
11%
Over the last year, the Revenue growth was 6%. The average annual Revenue growth rates for Bristol-Myers Squibb Co have been 1% over the past three years , 14% over the past five years , and 11% over the past ten years .
You don't have any saved screeners yet
